This review discusses various aspects of protein aggregation and inhibition strategies, emphasizing the use of polymers, which is one of the most promising approaches to combat various aggregation-induced complications in neurodegenerative diseases and protein therapeutics.

Protein aggregation limits the development of protein-based drugs, and leads to neurological disorders. In this study, the zwitterionic polymer, poly-sulfobetaine (p-SPB), was modified using the polyethylene glycol (PEG), and exhibited...